Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab is an investigational, T-cell bispecific antibody with a distinctive design that features 2 Fab arms for binding CD20 on B cells, along with 1 Fab arm for binding CD3 on T cells. The CD3 binding arm is fused directly to one of the CD20-binding arms in a head-to-tail fashion via a short flexible linker.
0.01M PBS, pH 7.4.
Research Grade Glofitamab Biosimilar
Bispecific,B-lymphocyte surface antigen B1,Membrane-spanning 4-domains subfamily A member 1,MS4A1,Leukocyte surface antigen Leu-16,B-lymphocyte antigen CD20,Bp35,CD20,T3E,T-cell surface antigen T3/Leu-4 epsilon chain,CD3e,T-cell surface glycoprotein CD3 epsilon chain
Protein A or G purified from cell culture supernatant.
Please contact with the lab for this information.
P11836 & P07766
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Bispecific, CD20-TCB (2:1), RG-6026, CAS: 2229047-91-8
For research use only. Not suitable for clinical or therapeutic use.